BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Stock Information for BiomX Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BiomX Inc.

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Announces a Mandatory Unit Separation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.